The estimated Net Worth of David Weill is at least $2.25 Million dollars as of 29 May 2024. David Weill owns over 1,193 units of TransMedics stock worth over $1,543,369 and over the last 5 years he sold TMDX stock worth over $493,538. In addition, he makes $211,077 as Independent Director at TransMedics.
Sign up
David Weill TMDX stock SEC Form 4 insiders trading
David has made over 6 trades of the TransMedics stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,193 units of TMDX stock worth $168,988 on 29 May 2024.
The largest trade he's ever made was exercising 21,645 units of TransMedics stock on 10 November 2022 worth over $346,320. On average, David trades about 3,979 units every 151 days since 2019. As of 29 May 2024 he still owns at least 10,732 units of TransMedics stock.
You can see the complete history of David Weill stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Weill biography
Dr. David Weill M.D. serves as Independent Director of the Company. He has served as a member of our Board since 2019 and has served since 2016 as Principal of the Weill Consulting Group, a biomedical consulting group focusing on organ transplantation and lung disease. Dr. Weill has been involved in the transplant and advanced lung disease fields for over 20 years, directing clinical programs and providing care to those afflicted with significant lung diseases. Dr. Weill served as Director of the Lung and Heart-Lung Transplant Program at Stanford University Medical Center from 2005 until 2016 and is the former Director of the Stanford Center for Advanced Lung Diseases. Dr. Weill received his Bachelor of Arts from Tulane University and his M.D. degree from Tulane University Medical School. He completed his Internship and Residency in Internal Medicine at Parkland Hospital, University of Texas Southwestern and his Fellowship in Pulmonary and Critical Care Medicine and Lung Transplantation at the University of Colorado at Denver and Health Sciences Center. Weill’s experience at a major medical research institute and his expertise in organ transplantation and pulmonary disease qualify him to serve as a member of our board of directors.
What is the salary of David Weill?
As the Independent Director of TransMedics, the total compensation of David Weill at TransMedics is $211,077. There are 6 executives at TransMedics getting paid more, with Waleed Hassanein having the highest compensation of $3,159,300.
How old is David Weill?
David Weill is 56, he's been the Independent Director of TransMedics since 2019. There are 5 older and 9 younger executives at TransMedics. The oldest executive at TransMedics Group, Inc. is James Tobin, 75, who is the Independent Chairman of the Board.
What's David Weill's mailing address?
David's mailing address filed with the SEC is C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, ANDOVER, MA, 01810.
Insiders trading at TransMedics
Over the last 5 years, insiders at TransMedics have traded over $99,976,312 worth of TransMedics stock and bought 154,333 units worth $3,250,328 . The most active insiders traders include Edwin M Jr Kania, Waleed H Hassanein und James R Tobin. On average, TransMedics executives and independent directors trade stock every 10 days with the average trade being worth of $2,982,476. The most recent stock trade was executed by Tamer I Khayal on 3 September 2024, trading 2,960 units of TMDX stock currently worth $98,065.
What does TransMedics do?
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
What does TransMedics's logo look like?
Complete history of David Weill stock trades at TransMedics
TransMedics executives and stock owners
TransMedics executives and other stock owners filed with the SEC include:
-
Waleed Hassanein,
President, Chief Executive Officer, Director -
Tamer Khayal,
Chief Commercial Officer -
Dr. Waleed H. Hassanein,
Founder, MD, CEO, Pres & Director -
Dr. Tamer I. Khayal,
Chief Commercial Officer -
Stephen Gordon,
CFO. Treasurer & Sec. -
Stephen Gordon,
Chief Financial Officer, Treasurer, Secretary -
David Weill,
Independent Director -
James Tobin,
Independent Chairman of the Board -
Thomas Gunderson,
Independent Director -
Edward Basile,
Independent Director -
Edwin Kania,
Independent Director -
John Sullivan,
Vice President - Quality and Engineering -
Miriam Provost,
Vice President - Global Regulatory Affairs -
Laura Damme,
Vice President - Clinical Affairs -
John Carey,
Vice President - Operations -
Susan Goodman,
VP of HR -
Mark Anderson,
Sr. Director of Technology Devel. -
Ike Okonkwo,
VP of Fin. & Accounting -
John F. Carey,
VP of Operations -
Therapeutics Corp Lung Biot...,
-
Ventures Fund Iv General Pa...,
-
Capital Management, L.P.Abr...,
-
Merilee Raines,
-
Capital Management, L.P.Abr...,
-
Rakesh P. Godhani,
Chief Digital Officer -
Nicholas Corcoran,
See Remarks -
Stephanie Lovell,
-
Anil P. Ranganath,
See remarks